---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-24-000879"
form_type: "8-K"
ticker: "ENTXW"
cik: "0001638097"
company_name: "Entera Bio Ltd."
filed_at: "2024-03-08T23:59:59+00:00"
generated_at: "2026-06-05T00:33:25.891442+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Entera Bio FY2023 net loss narrows to $8.9M; cash runway into Q2 2025; five oral peptide programs on track

## Summary
- Net loss for FY2023 was $8.9M ($0.31/share), down from $13.1M ($0.45/share) in FY2022.
- Cash and cash equivalents $11.0M as of Dec 31, 2023; sufficient to fund operations through Q2 2025.
- R&D expenses decreased to $4.5M from $5.8M; G&A decreased to $4.4M from $7.3M due to cost cuts.
- Key 2024 milestones: Phase 1 PK data for EB612 (H1), pre-IND PK for GLP-2 (H1) and OXM (mid-2024), SABRE update.
- Advancing five oral peptide programs: EB613 (osteoporosis), EB612 (hypoparathyroidism), GLP-2, OXM, stress fractures.

## SEC filing metadata
- accession: 0001178913-24-000879
- form_type: 8-K
- ticker: ENTXW
- cik: 0001638097
- company_name: Entera Bio Ltd.
- filed_at: 2024-03-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1638097/000117891324000879/0001178913-24-000879-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1638097/000117891324000879/zk2431116.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-24-000879
- JSON: https://secwatch.observer/filing/0001178913-24-000879.json
- Plain text: https://secwatch.observer/filing/0001178913-24-000879.txt

## Key facts
- Earnings Releases
  Entera Bio Ltd. reported financial results for the fiscal year ended December 31, 2023.
  - Period: the fiscal year ended December 31, 2023
  - Result: reported results
  source text: On March 8 , 2024, Entera Bio Ltd., a company organized under the laws of the State of Israel (“we,” “us,” “our” or the “Company”), issued a press release announcing its financial results for the fiscal year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1638097/000117891324000879/0001178913-24-000879-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.